Discounted Cash Flow
TG Therapeutics, Inc.
—
—
Average annual growth rates
| Metric | 10-Year | 5-Year | 3-Year |
|---|---|---|---|
| Sales | — | — | — |
| Free Cash Flow | — | — | — |
| Average (FCF & NI) | — | — | — |
| Net Income | — | — | — |
| Dividends | — | — | — |
Endpoint CAGR (better for long term trend)
| Metric | 10-Year | 5-Year | 3-Year |
|---|---|---|---|
| Sales | — | — | — |
| Free Cash Flow | — | — | — |
| Average (FCF & NI) | — | — | — |
| Net Income | — | — | — |
Projected growth rate
—
—
%
%
Historical inputs (10 fiscal years)
| YEAR | Sales | Net Income | Free Cash Flow | Net Margin | EPS (diluted) |
|---|---|---|---|---|---|
| 2016 | $323.0k | $-79.0m | $-61.9m | -24446.2% | $-1.60 |
| 2017 | $294.5k (-8.8%) | $-119.6m (-51.4%) | $-93.8m (-51.4%) | -40599.6% (-66.1%) | $-1.91 (-19.4%) |
| 2018 | $152.0k (-48.4%) | $-175.3m (-46.6%) | $-129.0m (-37.6%) | -115313.8% (-184.0%) | $-2.30 (-20.4%) |
| 2019 | $152.0k (0.0%) | $-174.3m (0.5%) | $-132.9m (-3.0%) | -114698.7% (0.5%) | $-1.96 (14.8%) |
| 2020 | $152.0k (0.0%) | $-279.9m (-60.6%) | $-214.9m (-61.6%) | -184159.9% (-60.6%) | $-2.42 (-23.5%) |
| 2021 | $6.7m (4300.7%) | $-348.1m (-24.4%) | $-296.0m (-37.8%) | -5204.1% (97.2%) | $-2.63 (-8.7%) |
| 2022 | $2.8m (-58.4%) | $-198.3m (43.0%) | $-176.2m (40.5%) | -7121.5% (-36.8%) | $-1.46 (44.5%) |
| 2023 | $233.7m (8290.0%) | $12.7m (106.4%) | $-31.4m (82.2%) | 5.4% (100.1%) | $0.09 (106.2%) |
| 2024 | $329.0m (40.8%) | $23.4m (84.5%) | $-40.6m (-29.1%) | 7.1% (31.1%) | $0.16 (77.8%) |
| 2025 | $616.3m (87.3%) | $447.2m (1812.4%) | $-25.0m (38.4%) | 72.6% (920.9%) | $3.10 (1837.5%) |
Base FCF: — (latest fiscal year)
Discount rate: % —
Terminal growth: —
Projection period: — years
Alt A decline yrs:
Alt B total yrs:
Projected cash flows
| Year | Projected cash flow | Discount Factor | Present Value |
|---|
PV of projected FCF: —
Terminal FCF: —
Terminal value: —
PV of terminal value: —
Enterprise value (DCF): —
Current price: —
—Alternative DCF Models
| Model | Fair Value | Upside | PV(FCFs) | PV(Terminal) | Total Years |
|---|---|---|---|---|---|
| Standard (10yr→TV) | — | — | — | — | 10 + TV |
| Alt A (Gradual Decline) | — | — | — | — | — |
| Alt B (30yr Hard Stop) | — | — | — | N/A | — |
This is a simplified DCF model for illustration. It uses reported free cash flow, a single growth assumption, fixed WACC, and a Gordon Growth terminal value. It is not investment advice.